PP451 Does NICE Reimburse Oncology Treatments Meeting End-Of-Life Criteria More Often Than Treatments That Do Not?

Introduction The National Institute of Health and Care Excellence (NICE) issued a supplementary advice in 2009 stating that treatments for patients with short life expectancies (<24 months) can exceed the cost-effectiveness threshold GBP30,000 (EUR34,668) per additional quality-adjusted life-year (QALY), as long treatment is indicated small patient populations there sufficient evidence it extends (≥ three months), compared current Service (NHS) treatments. This study investigated how often NICE reimburses meet end-of-life (EOL) criteria. Methods technology assessments (HTAs) conducted by from to 2020 were reviewed approved oncology drugs. Terminated appraisals excluded. Data regarding EOL criteria these submissions then gathered. HTA decisions divided into following categories: met; not applicable. A chi-square analysis was performed. Results total 316 reviews assessed final sample, which 71 percent (n = 223) positive. Out positive decisions, 43 96), 25 55), 32 72) met, applicable groups, respectively. showed significant correlation between (p 0.0008). These results consistent when “EOL applicable” group excluded 0.001). When performed met” met”, along possible 0.05). Conclusions oncology, more than attempt, but fail,